Circulating tumor cells (CTCs) are the seeds of cancer metastasis and can be accessed through a simple blood draw. Recent developments in nanomaterials and microfluidic devices have enabled the invention of highly sensitive microfluidic platforms such as the graphene oxide (GO) chip. Such novel microfluidic devices have drastically advanced the isolation and characterization of CTCs, revealing that these rare cells may reflect disease status in cancer patients. However, further investigations in the context of clinical treatment studies are still needed to fully elucidate the value of CTCs as biomarkers. Additionally, targeting these rare CTCs might be a feasible therapeutic strategy to control cancer metastasis. In this thesis work, I fir...
Rates of progression and treatment response in advanced prostate cancer are highly variable, necessi...
Circulating Tumor Cells (CTCs) are important biomarkers for monitoring tumor dynamics and efficacy o...
The classic biopsy approach does not allowmonitoring of primary tumor evolution over time, and sampl...
Metastasis in cancer patients is reflected by measurable levels of circulating tumor cells (CTCs) in...
Primary tumors shed thousands of cells into blood circulation every day. These circulating tumor cel...
Abstract Organ-specific metastasis is the primary cause of cancer patient death. The distant metasta...
Metastatic disease accounts for 90% deaths from cancer. As rare tumor cells shed from primary tumors...
Liquid biopsy of tumor through isolation of circulating tumor cells (CTCs) allows non-invasive, repe...
Cancer is a leading cause of death worldwide, and tumor heterogeneity presents a challenge for the c...
While accessible by a relatively noninvasive blood draw, circulating tumor cells (CTCs) remain diffi...
Cancer is a major cause of mortality worldwide, with a disease burden estimated to grow over the com...
Circulating tumor cells (CTCs) are shed from cancerous tumors, enter the circulatory system, and mig...
Circulating tumor cells (CTCs) are single cells or clusters of cells within the circulatory system o...
Circulating tumor cells (CTCs) are the seeds for cancer metastases development, which is responsible...
Circulating tumor cells have been a major area of focus for cancer metastasis research for the last ...
Rates of progression and treatment response in advanced prostate cancer are highly variable, necessi...
Circulating Tumor Cells (CTCs) are important biomarkers for monitoring tumor dynamics and efficacy o...
The classic biopsy approach does not allowmonitoring of primary tumor evolution over time, and sampl...
Metastasis in cancer patients is reflected by measurable levels of circulating tumor cells (CTCs) in...
Primary tumors shed thousands of cells into blood circulation every day. These circulating tumor cel...
Abstract Organ-specific metastasis is the primary cause of cancer patient death. The distant metasta...
Metastatic disease accounts for 90% deaths from cancer. As rare tumor cells shed from primary tumors...
Liquid biopsy of tumor through isolation of circulating tumor cells (CTCs) allows non-invasive, repe...
Cancer is a leading cause of death worldwide, and tumor heterogeneity presents a challenge for the c...
While accessible by a relatively noninvasive blood draw, circulating tumor cells (CTCs) remain diffi...
Cancer is a major cause of mortality worldwide, with a disease burden estimated to grow over the com...
Circulating tumor cells (CTCs) are shed from cancerous tumors, enter the circulatory system, and mig...
Circulating tumor cells (CTCs) are single cells or clusters of cells within the circulatory system o...
Circulating tumor cells (CTCs) are the seeds for cancer metastases development, which is responsible...
Circulating tumor cells have been a major area of focus for cancer metastasis research for the last ...
Rates of progression and treatment response in advanced prostate cancer are highly variable, necessi...
Circulating Tumor Cells (CTCs) are important biomarkers for monitoring tumor dynamics and efficacy o...
The classic biopsy approach does not allowmonitoring of primary tumor evolution over time, and sampl...